Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors inside the central anxious system, conolidine modulates alternate molecular targets. A Science Advances analyze discovered that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://lloydz852wro4.wiki-jp.com/user